Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA

Table 2

Cumulative virological responses in patients with chronic hepatitis B.

Undetectable; HBV-DNA (%)	ETV ()	TDF ()
4 weeks	4.8% (3/66)	0% (0/30)	0.60
12 weeks	34.8% (23/66)	43.3% (13/30)	0.43
24 weeks	56.1% (37/66)	63.3% (19/30)	0.50
36 weeks	69.7% (46/66)	90% (27/30)	0.03
48 weeks	86.4% (57/66)	96.7% (29/30)	0.13
72 weeks	93.9% (62/66)	96.7% (29/30)	0.58
96 weeks	96.9% (63/65)	96.7% (29/30)	0.58

TDF, tenofovir; ETV, entecavir; one patient was excluded because of adding adefovir for the virological breakthrough.